Equillium Inc.

2.74+0.0200+0.74%Vol 12.44K1Y Perf -55.48%
Aug 11th, 2022 15:59 DELAYED
BID2.44 ASK3.00
Open2.84 Previous Close2.72
Pre-Market- After-Market-
 - -  - -%
Target Price
13.40 
Analyst Rating
Strong Buy 1.00
Potential %
389.05 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
19.78 
Earnings Rating
Sell
Market Cap93.91M 
Earnings Date
9th Aug 2022
Alpha-0.01 Standard Deviation0.39
Beta1.36 

Today's Price Range

2.702.84

52W Range

1.667.12

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
1.48%
1 Month
25.69%
3 Months
22.32%
6 Months
-32.51%
1 Year
-55.48%
3 Years
-23.03%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
EQ2.740.02000.74
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.36-0.45-25.00
Q04 2021-0.34-0.36-5.88
Q03 2021-0.34-0.35-2.94
Q02 2021-0.31-0.310.00
Q01 2021-0.34-0.332.94
Q04 2020-0.38-0.365.26
Q03 2020-0.41-0.3124.39
Q02 2020-0.44-0.3715.91
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.40-5.26Negative
9/2022 QR-0.39-2.63Negative
12/2022 FY-1.52-8.57Negative
12/2023 FY-1.43-12.60Negative
Next Report Date-
Estimated EPS Next Report-0.40
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume12.44K
Shares Outstanding34.28K
Shares Float17.06M
Trades Count182
Dollar Volume34.11K
Avg. Volume24.21K
Avg. Weekly Volume26.20K
Avg. Monthly Volume17.25K
Avg. Quarterly Volume29.19K

Equillium Inc. (NASDAQ: EQ) stock closed at 2.74 per share at the end of the most recent trading day (a 0.74% change compared to the prior day closing price) with a volume of 12.44K shares and market capitalization of 93.91M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 26 people. Equillium Inc. CEO is Bruce D. Steel.

The one-year performance of Equillium Inc. stock is -55.48%, while year-to-date (YTD) performance is -27.32%. EQ stock has a five-year performance of %. Its 52-week range is between 1.66 and 7.12, which gives EQ stock a 52-week price range ratio of 19.78%

Equillium Inc. currently has a PE ratio of -1.00, a price-to-book (PB) ratio of 1.47, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -77.06%, a ROC of -79.96% and a ROE of -96.82%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Equillium Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.40 for the next earnings report. Equillium Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Equillium Inc. is Strong Buy (1), with a target price of $13.4, which is +389.05% compared to the current price. The earnings rating for Equillium Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Equillium Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Equillium Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 21.69, ATR14 : 0.23, CCI20 : 199.50, Chaikin Money Flow : 0.06, MACD : 0.12, Money Flow Index : 76.80, ROC : 28.91, RSI : 68.27, STOCH (14,3) : 85.57, STOCH RSI : 0.50, UO : 67.60, Williams %R : -14.43), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Equillium Inc. in the last 12-months were: Christine Zedelmayer (Option Excercise at a value of $57 168), Christine Zedelmayer (Sold 11 434 shares of value $62 715 ), Jason A. Keyes (Sold 26 000 shares of value $117 366 ), Stephen Connelly (Option Excercise at a value of $33 626), Stephen Connelly (Sold 8 092 shares of value $56 706 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Equillium Inc.

Equillium Inc is a biopharmaceutical company. It is developing novel immune-modifying therapies for severe immuno-inflammatory diseases. Its primary product candidate is itolizumab, which targets the CD6-ALCAM signaling pathway, which helps in the activity and trafficking of pathogenic effector T cells that drive inflammation in a number of diseases. Itolizumab is the treatment for multiple severe immuno-inflammatory disorders, including graft versus host disease, uncontrolled moderate to severe asthma and SLE / lupus nephritis.

CEO: Bruce D. Steel

Telephone: +1 858 412-5302

Address: 2223 Avenida De La Playa, La Jolla 92037, CA, US

Number of employees: 26

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

25%75%

Bearish Bullish

63%38%

Bearish Bullish

56%44%

Bearish Bullish

48%52%

TipRanks News for EQ


News

Stocktwits